Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer.
52W Range
2ndpctl
Volume
0.32×avg
Market Cap
16.94MUSD
P/E Ratio
-0.2TTM
Div Yield
-ann
Loading chart data...
Current StateState loading
Tempest Therapeutics, Inc.
TPSTNASDAQ Capital Market·USD·Closed
Tempest Therapeutics, Inc.
TPSTNASDAQ·USD·Closed
$1.06
−1.85%
$1.06
−$0.02 (1.85%)
52W Range
2ndpctl
Volume
0.32×avg
Mkt Cap
16.94MUSD
P/E
-0.2TTM
Div Yield
–ann
TPST: Tempest Therapeutics, Inc. Stock Analysis | finqOS
